## IBEX Maintains Upward Momentum ### Continued growth in exosome analysis market **Sunnyvale Calif. – Oct. 12, 2022** – IBEX, a liquid biopsy company dedicated to developing transformative cell-free nucleic acid (cfNA) blood tests for earlier cancer detection and personalized monitoring, today announced continued growth in their exosome analysis market, with new partnerships and industry recognitions. ### Blood-based biomarker discovery and clinical diagnostics IBEX’s mission is to transform cancer care with cfNA blood tests. Its highly sensitive and specific cfNA platform can be used to detect and monitor cancer earlier and more accurately than traditional methods. IBEX is also developing companion diagnostic tests to guide treatment decisions and monitor response to therapy. ### Overcoming the challenges of exosome analysis One of the challenges in exosome analysis is the low concentration of exosomes in blood. IBEX has overcome this challenge by developing a proprietary cfNA platform that can isolate and analyze exosomes with high efficiency. The platform is also highly multiplexed, allowing for the detection of multiple biomarkers from a single sample. ### Growth in exosome analysis products and services The growth in IBEX's exosome analysis market is being driven by the increasing demand for more accurate and sensitive cancer diagnostics. IBEX is well-positioned to meet this demand with its innovative cfNA platform, and the company is expected to continue to see strong growth in the coming years.
Comments